Radiopharm launches A$5M share purchase plan

Radiopharm Theranostics (RADX) received firm commitments from international and Australian institutional and industry investors , including Lantheus Holdings (LNTH), to raise approximately A$35M by way of a private placement of 1,167 million new fully paid ordinary shares in the Company at a price of A$0.03 per share. Under the Placement, Placement Subscribers are anticipated to receive one free attaching option for every one Placement Share subscribed for under the Placement. The Attaching Options will have an exercise price of A$0.039 per option with an expiration of 31 October 2027 and will be subject to shareholder approval. It is intended that the Attaching Options will be quoted on the ASX. The full details of the rights and liabilities attaching to the Attaching Options are annexed to this announcement. The Placement is being followed by a Share Purchase Plan, to raise up to A$5M, for existing eligible shareholders with registered addresses in Australia or New Zealand, with applications up to a maximum of A$30,000. The SPP will be made to Eligible Shareholders on the same terms as the Placement and the Attaching Options issued under the SPP will be subject to shareholder approval. The funds raised from the Placement and SPP, together with the company’s existing cash balance1 will be used for: Drug Manufacturing – A$6m; Clinical Trials – A$34m; and Administration, working capital, corporate costs and offer costs – A$19m. RAD has received firm commitments from institutional and sophisticated investors for a A$35 million Placement of approximately 1,167 million Placement Shares in the Company to Placement Subscribers for the Placement Price. The Placement Price represents a discount of: 18.9% to the last close of A$0.037 on 15 October 2025; and 17.6% to the 5-day VWAP of A$0.036 up to and including 15 October 2025. 11.8% to the 15-day VWAP of A$0.034 up to and including 15 October 2025. Lantheus continues support as strategic investor with A$7.6M investment in the Placement. A$12.5M will be issued on Friday, 24 October 2025, using RAD’s existing placement capacity with ~326.6M Placement Shares to be issued under Listing Rule 7.1 and ~89.1 million Placement Shares to be issued Listing Rule 7.1A. The remaining A$22.5M will be issued subject to shareholder approval at an upcoming Extraordinary General Meeting. Subject to shareholder approval at an upcoming EGM, Placement Subscribers will also receive one Attaching Option for every one Placement Share issued, with an exercise price of A$0.039 and an expiry date of 31 October 2027, a total of ~1,167 million Attaching Options. The Placement Shares to be issued will rank equally with existing RAD fully paid ordinary shares. An EGM to approve the Tranche 2 Placement and the Attaching Options is anticipated to be held in early December 2025.